(redirected from Mammalian target of rapamycin)
Also found in: Wikipedia.
mTORMammalian Target of Rapamycin (a protein)
mTORMan, Technology, Organisation and Risk Management
Copyright 1988-2018, All rights reserved.
References in periodicals archive ?
Antidepressant-like effect of ascorbic acid is associated with the modulation of mammalian target of rapamycin pathway.
These pathways include the Aryl Hydrocarbon Receptor, the scavenger receptor CD-36, the cyclooxygenase 2 and its beneficial prostaglandin products, and the mammalian Target of Rapamycin protein.
Mammalian target of rapamycin (mTOR) is a master sensor of energy status and will be inhibited in the state of energy depletion.[15] Myocardial energy depletion plays a major role in myocardial dysfunction during sepsis.[16],[17] There are little data describing the role of the mTOR pathway during sepsis in the heart.[18] Furthermore, among various pathways known to regulate autophagy in mammalian cells, mTOR complex 1 (mTORC1)/S6 kinase-1 (S6K1) signaling pathway is one of the best-understood pathways.[19] Accumulating evidence has indicated that the mTORC1/S6K1 pathway negatively regulates autophagy, so the relationship between the mTOR pathway and the change of autophagy process in cecal ligation and puncture (CLP)-induced myocardial dysfunction was investigated in this study.
The mechanism involves a previously unknown protein complex called mammalian target of rapamycin complex 3 (mTORC3).
Standing originally for mammalian Target of Rapamycin (and more recently mechanistic Target of Rapamycin), mTOR is an enzymatic complex that drives growth in humans and other organisms.
This process is regulated by the mammalian target of rapamycin (mTOR) and AMP-activated protein kinases (AMPK)."
Afinitor works by inhibiting the mammalian target of rapamycin (mTOR), a protein that regulates multiple cellular functions.
"We caution other clinicians with similar patients that further data on the safety and efficacy of mammalian target of rapamycin inhibitors are required before their use can be recommended for patients with DIPNECH syndrome," the authors write.
She added:"Metformin upregulated activated protein kinase (AMPK) in breast adenocarcinoma resulting in subsequent inhibition of the mammalian target of rapamycin (mTOR).
Outcomes of unselected patients with metastatic clear-cell renal cell carcinoma treated with first-line pazopanib therapy followed by vascular endothelial growth factor receptor tyrosine kinase inhibitors or mammalian target of rapamycin inhibitors: A single-institution experience.
Soukas, "Identification of Akt-independent regulation of hepatic lipogenesis by mammalian target of rapamycin (mTOR) complex 2," The Journal of Biological Chemistry, vol.